Table.
Randomized Control Trials evaluating CD34+ bone marrow-derived stem cell therapy for Acute Myocardial Infarction
| Source | Sample size |
Cell type | Number of cells |
Route of injection |
Results |
|---|---|---|---|---|---|
| AMI | |||||
| Tendera et al. 2009 |
200 | CD34+ | NA | IC | No significant improvement |
| Quyyumi et al. 2011 | 31 | CD34+ | 5–15×106 | IC | Dose dependent perfusion improvement |
| Quyyumi et al. 2016 | 161 | CD34+ | 8–43×106 | IC | No significant improvement |
| ICM | |||||
| Patel et al. 2005 |
20 | CD34+ | NR | IM | Improved EF |
| Refractory Angina | |||||
| Losordo et al. 2007 |
24 | Peripheral CD34+ + G-CSF |
NR | IM | No significant improvement |
| Losordo et al. 2011 | 167 | Peripheral CD34+ + G-CSF |
1–5×105/ Kg |
IM | Improved angina and exercise tolerance in low dose group |
| Henry et al. 2016 |
112 | Peripheral CD34+ + G-CSF |
1–100 ×105/Kg |
IM | Early termination of study Reduced angina frequency |
| NIDCM | |||||
| Vrtovec et al. 2013 |
110 | Peripheral CD34+ + G-CSF |
1.13±0.26 ×108 |
IC | Improved EF, 6MWD Decreased NT-pro-BNP Lower mortality for stem cell treatment |
| Vrtovec et al. 2016 |
45 | Peripheral CD34+ + G-CSF |
1.27– 2.16×108 |
IM | No response in diabetics Increased EF, decreased NT-pro-BNP in non- diabetics |
Abbreviations: AMI, acute myocardial infarction; EF, ejection fraction; G-CSF, granulocyte-colony stimulating factor; IC, intracoronary; ICM, ischemic cardiomyopathy; IM, intramuscular; NA, not available; NIDCM, non-ischemic dilated cardiomyopathy; NR, not reported; RCT, randomized controlled trial